Cancer cells use EVs to transfer oncogenic ALK to normal cell in the surrounding tumor microenvironment and confer resistance to neighboring drug-sensitive cancer cells, via activation of the MAPK pathway [99]. This evidence concerns the gene ALK and cancer.